Ethical Overkill: Institutions should take a unified look at protections for research on human subjects
By Editorial,
Nature
| 12. 09. 2014
The most important resource needed to conduct research on humans, it is said, is not brainpower or money: it is trust. In the United States, as elsewhere, hundreds of institutions and thousands of investigators work to protect that trust by carefully evaluating proposals for clinical trials and other research that uses human subjects.
Each US institution hosting such a study typically conducts its own ethical review of the proposal. The review process serves many functions: it is an expression of the responsibility that these investigators feel towards protecting their local community, an opportunity to tweak protocols to adapt to the community’s specific needs, and a protection against potential lawsuits resulting from a flawed research protocol.
Sadly, evidence suggests that much of this effort is misplaced. A 2010 survey of 45 institutions reviewing the same protocol found that local scrutiny resulted in no substantial changes (B. Ravina et al. Ann. Neurol. 67, 258–260; 2010). Instead, most alterations simply inserted standardized institutional language — unrelated to the proposed study — to the informed-consent document signed by research participants before they...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Miguel Muñoz, Cadena SER | 08.04.2026
"Para ellos, una familia numerosa no solo es una preferencia personal, sino que es una obligación. Creen que tener tantos hijos como sea posible es necesario para evitar un futuro apocalíptico", aseguraba Xavier Orri, periodista y cofundador de Página Internacional...